To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

IV and topical TXA superior to placebo for hematological outcomes after PLIF

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
April 2019

IV and topical TXA superior to placebo for hematological outcomes after PLIF

Vol: 8| Issue: 4| Number:36| ISSN#: 2564-2537
Study Type:Randomized Trial
OE Level Evidence:2
Journal Level of Evidence:N/A

Intravenous Administration of Tranexamic Acid Significantly Reduces Visible and Hidden Blood Loss Compared with Its Topical Administration for Double-Segment Posterior Lumbar Interbody Fusion: A Single-Center, Placebo-Controlled, Randomized Trial

World Neurosurg. 2019 Feb;122:e821-e827.

Contributing Authors:
J Wei Z Li C Wang X Mu Y Ou D Yin B Liang D Qiu

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

150 patients with lumbar degenerative disease and scheduled for a posterior lumbar interbody fusion procedure were randomized to receive intravenous TXA, topical TXA or placebo for blood loss. Outcomes of interest included hemoglobin, hematocrit and fibrinogen levels, prothrombin time, extubation time, hospital length of stay, post-operative Visual Analog Scale (VAS), intra-operative blood loss, d...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.